Syndax Pharmaceuticals SNDX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$16.66M (6 inflow days, 14 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 34.8% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 25.65% to 21.19% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Franklin Resources | Mutual Fund | 2026/Q3 | +1,200,281 | 3.9% |
| Loomis, Sayles & Company L.P. | Mutual Fund | 2026/Q3 | +412,204 | 1.5% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +298,850 | 2.5% |
| Centerbook Partners LP | Hedge Fund | 2026/Q3 | +273,253 | 0.3% |
| BlackRock | Mutual Fund | 2026/Q3 | +248,454 | 10.3% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +1,854,436 | 2.3% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,228,348 | 6.3% |
| Loomis, Sayles & Company L.P. | Mutual Fund | 2026/Q3 | +923,624 | 1.0% |
| Candriam, Société En Commandite Par Actions | Mutual Fund | 2026/Q3 | +770,708 | 1.9% |
| BlackRock | Mutual Fund | 2026/Q3 | +765,580 | 10.1% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +751,614 | 2.3% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +669,815 | 6.1% |
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +579,700 | 1.7% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +456,700 | 0.5% |
| Qube Research & Technologies Ltd | Mutual Fund | 2026/Q3 | +441,135 | 0.5% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 8 Nov 2026 | Aaron Ondrey | CFO, Principal Accounting and Financial Officer & Treasurer | Other Derivative Acquisition | +270,000 | $9.55 | – |
| 28 Oct 2026 | Dennis Podlesak | Independent Chairperson | Derivative Exercise and Sale | -8,000 | $14.21 | 14,430 |
| 7 Jul 2026 | Michael Metzger | Chief Executive Officer | Derivative Exercise and Sale | -32,375 | $24.24 | 63,160 |
| 11 Jun 2026 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -31,235 | $18.14 | – |
| 11 Jun 2026 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -53,750 | $18.14 | 60,885 |
| 10 Jun 2026 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Automatic Disposition | -11,765 | $18.00 | 60,885 |
| 31 May 2026 | Keith Goldan | Officer | Open Market Disposition | -1,177 | $18.99 | 27,902 |
| 31 May 2026 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -6,847 | $18.99 | 63,160 |
| 8 Feb 2026 | Keith Goldan | Officer | Open Market Disposition | -3,410 | $21.03 | 29,079 |
| 8 Feb 2026 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -17,159 | $21.03 | 70,007 |
| 5 Feb 2026 | Keith Goldan | Officer | Open Market Disposition | -2,082 | $20.62 | 20,822 |
| 5 Feb 2026 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -7,412 | $20.62 | 87,166 |
| 3 Feb 2026 | Keith Katkin | Independent Director | Other Acquisition | +24,000 | – | 49,000 |
| 3 Feb 2026 | Pierre Legault | Independent Director | Other Acquisition | +24,000 | – | 114,000 |
| 3 Feb 2026 | Keith Goldan | Officer | Other Acquisition | +52,250 | – | 123,017 |
| 3 Feb 2026 | Keith Goldan | Officer | Other Derivative Acquisition | +118,000 | $20.43 | 118,000 |
| 3 Feb 2026 | Dennis Podlesak | Independent Chairperson | Other Acquisition | +48,000 | – | 225,333 |
| 3 Feb 2026 | Michael Metzger | Chief Executive Officer | Other Acquisition | +217,600 | – | 421,683 |
| 3 Feb 2026 | Michael Metzger | Chief Executive Officer | Other Derivative Acquisition | +440,000 | $20.43 | 440,000 |
| 3 Feb 2026 | Jennifer Jarrett | Independent Director | Other Acquisition | +24,000 | – | 114,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 18,920,163 | 21.2% | 6.4 |
| 15 Oct 2026 | 18,001,644 | 20.2% | 7.6 |
| 30 Sep 2026 | 18,234,880 | 20.4% | 8.5 |
| 15 Sep 2026 | 20,660,449 | 23.1% | 14.7 |
| 31 Aug 2026 | 21,681,907 | 24.3% | 19.7 |
| 14 Aug 2026 | 22,902,431 | 25.6% | 15.0 |
No comments yet — be the first to weigh in on SNDX.
Sign in to join the discussion.